Abstract
Background India had an estimated 2.9 million tuberculosis cases and 506 thousand deaths in 2021. Novel vaccines effective in adolescents and adults could reduce this burden. M72/AS01E and BCG-revaccination have recently completed Phase IIb trials and estimates of their population-level impact are needed. We estimated the potential health and economic impact of M72/AS01E and BCG-revaccination in India and investigated the impact of variation in vaccine characteristics and delivery strategies.
Methods We developed an age-stratified compartmental tuberculosis transmission model for India calibrated to country-specific epidemiology. We projected current trends to 2050 assuming no-new-vaccine introduction, and M72/AS01E and BCG-revaccination scenarios over 2025–2050 exploring uncertainty in product characteristics and implementation. We estimated reductions in tuberculosis cases and deaths by each scenario compared to no-new-vaccine introduction, as well as costs and cost-effectiveness from health-system and societal perspectives.
Results M72/AS01E scenarios were predicted to avert 40% more tuberculosis cases and deaths by 2050 compared to BCG-revaccination scenarios. Cost-effectiveness ratios for M72/AS01E vaccines were around seven times higher than BCG-revaccination, but nearly all scenarios were cost-effective. The estimated average incremental cost was US$190 million for M72/AS01E and US$23 million for BCG-revaccination per year. Sources of uncertainty included whether M72/AS01E was efficacious in uninfected individuals at vaccination, and if BCG-revaccination could prevent disease.
Conclusions M72/AS01E and BCG-revaccination could be impactful and cost-effective in India. However, there is great uncertainty in impact, especially with varying vaccine characteristics. Greater investment in vaccine development and delivery is needed to raise the probability of success.
Competing Interest Statement
RCH reports employment by Sanofi Pasteur, unrelated to tuberculosis and outside the submitted work. NAM received consulting fees from The Global Fund to Fight AIDS, Tuberculosis and Malaria, and the WHO, and reports funding to their institution from the U.S. Centers for Disease Control and Prevention, the Bill & Melinda Gates Foundation, NIH, and U.S. Council of State and Territorial Epidemiologists. RGW is also funded for other work by the Wellcome Trust (218261/Z/19/Z), NIH (1R01AI147321-01), EDCTP (RIA208D-2505B), UK MRC (CCF 17-7779 via SET Bloomsbury), ESRC (ES/P008011/1), BMGF (OPP1084276, OPP1135288 & INV-001754), and the WHO. All other authors declare no conflicts of interest.
Funding Statement
We thank the Bill & Melinda Gates Foundation for providing funding (INV-001754) to undertake this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Epidemiologic data used are available from the World Health Organization Global TB Report CSV files to download (https://www.who.int/teams/global-tuberculosis-programme/data) and summarised in the Supplementary Material. Population estimates and projections are available from the United Nations Department of Economic and Social Affairs World Population Prospects 2019 (https://population.un.org/wpp/Download/Standard/Population/). Analytic code will be made available at https://doi.org/10.5281/zenodo.6421372 immediately following publication indefinitely for anyone who wishes to access the data for any purpose.
List of Abbreviations
- BCG
- Bacillus Calmette–Guérin
- DALY
- Disability-adjusted life years
- ICER
- Incremental cost-effectiveness ratio
- Mtb
- Mycobacterium tuberculosis
- NTEP
- National Tuberculosis Elimination Programme
- WHO
- World Health Organization
